

This publication was downloaded for exclusive use by: fanzhihe@enn.cn

Flashnote 26 October 2021

China

## EQUITIES


AShare  
Research600803 CH Outperform  
Price (at 08:51, 26 Oct 2021 GMT) Rmb17.72

Valuation	Rmb	23.20
- Sum of Parts		
12-month target	Rmb	23.20
Upside/Downside	%	+30.9
12-month TSR	%	+32.7
Volatility Index		Medium
GICS sector		Utilities
Market cap	Rmbm	50,429
Market cap	US\$m	7,903
Free float	%	45
30-day avg turnover	US\$m	43.1
Number shares on issue	m	2,846

## Investment fundamentals

Year end 31 Dec		2020A	2021E	2022E	2023E
Revenue	bn	88.1	102.0	134.8	153.0
EBIT	bn	10.6	12.9	14.5	16.1
EBIT growth	%	724.2	21.3	12.7	10.5
Reported profit	bn	2.1	3.1	3.7	4.2
Adjusted profit	bn	2.1	3.1	3.7	4.2
EPS rep	Rmb	0.82	1.13	1.33	1.51
EPS rep growth	%	-17.8	38.9	17.4	13.9
EPS adj	Rmb	0.82	1.13	1.33	1.51
EPS adj growth	%	-17.7	38.7	17.4	13.9
PER rep	x	21.7	15.6	13.3	11.7
PER adj	x	21.7	15.6	13.3	11.7
Total DPS	Rmb	0.19	0.27	0.35	0.44
Total div yield	%	1.1	1.5	2.0	2.5
ROA	%	15.9	11.3	11.6	11.6
ROE	%	24.1	33.2	30.5	28.1
EV/EBITDA	x	5.2	3.9	3.5	3.2
Net debt/equity	%	35.8	19.8	6.6	0.4
P/BV	x	5.6	4.6	3.7	3.0

## 600803 CH rel CSI 300 performance, &amp; rec history



Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period.

Source: FactSet, Macquarie Research, October 2021

(all figures in Rmb unless noted, TP in CNY)

## Analysts

Macquarie Securities (Australia) Limited



**Mark Wiseman, CFA** +61 418 375 283  
mark.wiseman@macquarie.com

Macquarie Capital Limited



**Kerry Cheng** +86 21 2412 9025  
kerry.cheng@macquarie.com

## ENN Natural Gas Co (600803 CH) Zhoushan LNG Terminal injection is coming

### 90% Zhoushan Terminal to be injected

- ENN Natural Gas (ENG) announced to inject 90% Zhoushan LNG Terminal via share placement and cash on 26 Oct after market close. The stock will resume trading from 27 Oct.

### 8mtpa LNG capacity to create long-term synergies

- **Valuation of the deal to be announced.** ENG guided the valuation of Zhoushan Terminal and payment details are still under review. Thus we are not sure how much shares to be issued at this moment.
  - **The 90% shares of Zhoushan Terminal will be bought from ENN Technology (70%), ENN Group (15%), ENN Holding (5%), all controlled by Mr. Wang Yusuo.** The remaining 10% is owned by Prism Energy. After the deal, Zhoushan Terminal's financial statement will be consolidated under ENG.
  - **Zhoushan LNG Terminal LT capacity likely to reach 8mtpa.** Phase I of the Terminal was launched in 2018, and Phase II started trial operation from Jun-2021. Total capacity of the Terminal will reach 5mtpa after it fully ramps up in the near term and mgmt. guided LT annual capacity will reach 8mtpa, ~30%-40% of ENN/ENG's retail gas sales volume.
  - **Synergies to be created through securing and integrating upstream LNG sources with its gas distributor business.** We think the asset injection signals an important move of ENG to differentiate itself from gas distributor peers in terms of better ability to lock down enough upstream sources both in ST (when gas is in tight supply) and LT.
- Action and recommendation**
- Reiterate Outperform. We expect more details to be disclosed during the briefing, which will be held at 8:30am Beijing Time, 27 October.

## Important disclosures:

## Recommendation definitions

## Macquarie – Asia and USA

Outperform – expected return >10%  
Neutral – expected return from -10% to +10%  
Underperform – expected return <-10%

## Macquarie – Australia/New Zealand

Outperform – expected return >10%  
Neutral – expected return from 0% to 10%  
Underperform – expected return <0%

Note: expected return is reflective of a Medium Volatility stock and should be assumed to adjust proportionately with volatility risk

## Volatility index definition\*

This is calculated from the volatility of historical price movements.

**Very high-highest risk** – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative.

**High** – stock should be expected to move up or down at least 40–60% in a year – investors should be aware this stock could be speculative.

**Medium** – stock should be expected to move up or down at least 30–40% in a year.

**Low-medium** – stock should be expected to move up or down at least 25–30% in a year.

**Low** – stock should be expected to move up or down at least 15–25% in a year.

\* Applicable to select stocks in Asia/Australia/NZ

**Recommendations** – 12 months

**Note:** Quant recommendations may differ from Fundamental Analyst recommendations

## Financial definitions

All "Adjusted" data items have had the following adjustments made:

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense  
Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

**EPS** = adjusted net profit / epowa\*

**ROA** = adjusted ebit / average total assets

**ROA Banks/Insurance** = adjusted net profit / average total assets

**ROE** = adjusted net profit / average shareholders funds

**Gross cashflow** = adjusted net profit + depreciation

\*equivalent fully paid ordinary weighted average number of shares

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

## Recommendation proportions – For quarter ending 30 Sept 2021

	AU/NZ	Asia	USA	
Outperform	62.76%	67.53%	74.19%	(for global coverage by Macquarie, 4.72% of stocks followed are investment banking clients)
Neutral	31.03%	21.83%	24.73%	(for global coverage by Macquarie, 3.23% of stocks followed are investment banking clients)
Underperform	6.21%	10.64%	1.08%	(for global coverage by Macquarie, 0.00% of stocks followed are investment banking clients)

## 600803 CH vs HSI, &amp; rec history



(all figures in CNY currency unless noted)

Note: Recommendation timeline – if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period.  
Source: FactSet, Macquarie Research, October 2021

## 12-month target price methodology

600803 CH: Rmb23.20 based on a Sum of Parts methodology

## Company-specific disclosures:

Important disclosure information regarding the subject companies covered in this report is available publicly at [www.macquarie.com/research/disclosures](http://www.macquarie.com/research/disclosures). Clients receiving this report can additionally access previous recommendations (from the year prior to publication of this report) issued by this report's author at <https://www.macquarieinsights.com>.

Date	Stock Code (BGB code)	Recommendation	Target Price
24-Aug-2021	600803 CH	Outperform	Rmb23.20
11-Aug-2021	600803 CH	Outperform	Rmb23.50
03-Feb-2021	600803 CH	Outperform	Rmb21.00
30-Oct-2020	600803 CH	Outperform	Rmb15.60
16-Sep-2020	600803 CH	Outperform	Rmb15.00
17-Jul-2020	600803 CH	Outperform	Rmb16.70

## Target price risk disclosures:

**600803 CH:** Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

## Sensitivity analysis:

Clients receiving this report can request access to a model which allows for further in-depth analysis of the assumptions used, and recommendations made, by the author relating to the subject companies covered. To request access please contact [insights@macquarie.com](mailto:insights@macquarie.com).

## Analyst certification:

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Ltd total revenues, a portion of which are generated by Macquarie Group's Investment Banking activities.

## General disclaimers:

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Limited, Taiwan Securities Branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. Members of the Macro Strategy team are Sales & Trading personnel who provide desk commentary that is not a product of the Macquarie Research department or subject to FINRA Rule 2241 or any other regulation regarding independence in the provision of equity research.

#### Country-specific disclaimers:

**Australia:** In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organization of the Australian Securities Exchange. Macquarie Securities (Australia) Limited staff involved with the preparation of research have regular interaction with companies they cover. Additionally, Macquarie Group Limited does and seeks to do business with companies covered by Macquarie Research. There are robust information barriers in place to protect the independence of Macquarie Research's product. However, recipients of Macquarie Research should be aware of this potential conflict of interest. **New Zealand:** In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. **United Kingdom and the EEA:** In the United Kingdom and the European Economic Area, research is distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). **Hong Kong & Mainland China:** In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Limited. **Japan:** In Japan, research is issued and distributed by Macquarie Capital Securities (Japan) Limited (Tokyo Branch), the Financial Instruments Business Operator, registered with the Financial Services Agency (Registration number: Kanto Financial Bureau (FIBO) No. 231), the member of the Tokyo Stock Exchange, Inc., Osaka Exchange, Inc. and the member of Japan Securities Dealers Association. Its Designated Dispute Resolution Institution is Financial Instruments Mediation Assistance Center ("FINMAC"). **India:** In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt. Ltd. (CIN: U65920MH1995PTC090696), 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India, which is a SEBI registered Research Analyst having registration no. INH000000545. During the past 12 months, Macquarie Group Limited or one of its affiliates may have provided securities services to companies mentioned in this report for which it received compensation for Broking services. **Malaysia:** In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 199801007342 (463469-W)) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Macquarie may be an Issuer of Structured Warrants on securities mentioned in this report. **Taiwan:** In Taiwan, research is issued and distributed by Macquarie Capital Limited, Taiwan Securities Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. The recipient of this report shall not engage in any activities which may give rise to potential conflicts of interest to the report. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Macquarie may be in past one year or now being an Issuer of Structured Warrants on securities mentioned in this report. **Thailand:** In Thailand, research is produced, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: <http://www.thai-iod.com/en/publications.asp?type=4>. Macquarie Securities (Thailand) Limited may be an issuer of derivative warrants on the securities mentioned in this report. **South Korea:** In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at <http://dis.kofia.or.kr/websquare/index.jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystStut.xml&divisionId=MDIS03002001000000&serviceId=SDIS03002001000>. **Singapore:** In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. Singapore recipients should contact Macquarie Capital Securities (Singapore) Pte Ltd at +65 6601 0888 for matters arising from, or in connection with, this report. **United States:** In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc. accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at [www.macquarie.com/research/disclosures](http://www.macquarie.com/research/disclosures), or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Capital (USA) Inc, 125 W.55th Street, New York, NY 10019. **Canada:** In Canada, research is distributed by Macquarie Capital Markets Canada Ltd., a (i) member of the Investment Industry Regulatory Organization of Canada (IIROC) and the Canadian Investor Protection Fund, and (ii) participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Important disclosure

information regarding the subject companies covered in this report is available at [www.macquarie.com/research/disclosures](http://www.macquarie.com/research/disclosures). IIROC Rule 3400  
Disclosures can be obtained by writing to Macquarie Capital Markets Canada Ltd., 181 Bay St. Suite 3100, Toronto, ON M5J2T3.

© **Macquarie Group**

## Equities

## Asia Research

## Head of Equity Research

Jake Lynch (Asia)	(852) 3922 3583
Damian Thong (Japan)	(813) 3512 7877
Jayden Vantarakis (ASEAN)	(6221) 2598 8310

## Strategy, Country

Viktor Shvets (Asia, Global)	(852) 3922 3883
David Ng (China, Hong Kong)	(852) 3922 1291
David Ching (China)	(852) 3922 1823
Erica Chen (China A)	(8621) 2412 9024
Damian Thong (Japan)	(813) 3512 7877
Daniel Kim (Korea)	(822) 3705 8641
Jeffrey Ohlweiler (Taiwan)	(8862) 2734 7512
Jayden Vantarakis (ASEAN, Singapore)	(6221) 2598 8310
Ari Jahja (Indonesia)	(6221) 2598 8366
Ben Shane Lim (Malaysia)	(603) 2059 8868
Gilbert Lopez (Philippines)	(632) 857 0892
Peach Patharavanakul (Thailand)	(662) 694 7753
Aditya Suresh (India)	(852) 3922 1265
Charles Yonts (Asia ESG)	(852) 3922 5832
John Conomos (APAC Quant)	(61) 412 621 678
Felix Rusli (Asia Product)	(852) 3922 4283

## Digital Transformation

John Wang (Greater China)	(852) 3922 3578
Ellie Jiang (Greater China)	(852) 3922 4110
Dexter Hsu (Greater China)	(8862) 2734 7530
Hiroshi Yamashina (Japan)	(813) 3512 5968
Masahiro Mochizuki (Japan)	(813) 3512 7868
Andy Kim (Korea)	(822) 3705 8690
Zhiwei Foo (Singapore)	(65) 6601 0465
Abhishek Bhandari (India)	(9122) 6720 4088

## Energy Transition

Mark Wiseman (Asia)	(612) 8232 8417
Kerry Cheng (Greater China)	(8621) 2412 9025
Masahiro Mochizuki (Japan)	(813) 3512 7868
Yasuhiro Nakada (Japan)	(813) 3512 7862
Anna Park (Korea)	(822) 3705 8669
Ben Shane Lim (Malaysia)	(603) 2059 8868
Yupapan Polpornprasert (Thailand)	(662) 694 7729
Aditya Suresh (India)	(852) 3922 1265

## Lifestyle

Linda Huang (Asia)	(852) 3922 4068
Terence Chang (Greater China)	(852) 3922 3581
Sunny Chow (Greater China)	(852) 3922 3768
Leon Rapp (Japan)	(813) 3512 7879
Shentao Tang (Japan)	(813) 3512 7851
Akshay Sugandi (Indonesia)	(6221) 25988369
Karisa Magpayo (Philippines)	(632) 857 0899
Chaline Congmuang (Thailand)	(662) 694 7993
Avi Mehta (India)	(9122) 6720 4031

## Technology

Nicolas Baratte (Asia)	(852) 3922 5801
Damian Thong (Asia)	(813) 3512 7877
Jeffrey Ohlweiler (Greater China)	(8862) 2734 7512
Cherry Ma (Greater China)	(852) 3922 5800
Erica Chen (Greater China)	(8621) 2412 9024
Kaylin Tsai (Greater China)	(8862) 2734 7523
Hiroshi Taguchi (Japan)	(813) 3512 7867
Yasuhiro Nakada (Japan)	(813) 3512 7862
Daniel Kim (Korea)	(822) 3705 8641
Sonny Lee (Korea)	(822) 3705 8678

## Automation &amp; Mobility

James Hong (Asia)	(822) 3705 8661
David Ching (Greater China)	(852) 3922 1823
Erica Chen (Greater China)	(8621) 2412 9024
Wendy Pan (Japan)	(813) 3512 7875
Anna Park (Korea)	(822) 3705 8669
Sonny Lee (Korea)	(822) 3705 8678
Ashish Jain (India)	(9122) 6720 4063
Ajinkya Bhat (India)	(9122) 6720 4052

## Health

David Ng (Greater China)	(852) 3922 1291
Ari Jahja (ASEAN, Indonesia)	(6221) 2598 8366
Alankar Garude (India)	(9122) 6720 4134

## Commanding Heights

Jayden Vantarakis (ASEAN, Indonesia, Singapore)	(6221) 2598 8310
Derrick Heng (Singapore)	(65) 6601 0436
Ben Shane Lim (Malaysia)	(603) 2059 8868
Aiman Mohamad (Malaysia)	(603) 2059 8986
Ben Shane Lim (Malaysia)	(603) 2059 8868
Gilbert Lopez (Philippines)	(632) 857 0892
Peach Patharavanakul (Thailand)	(662) 694 7753
Suresh Ganapathy (India)	(9122) 6720 4078

## Find our research at

Macquarie: [www.macquarieinsights.com](http://www.macquarieinsights.com)  
 Refinitiv: [www.refinitiv.com](http://www.refinitiv.com)  
 Bloomberg: MAC GO  
 Factset: <http://www.factset.com/home.aspx>  
 CapitalIQ: [www.capitaliq.com](http://www.capitaliq.com)  
 Contact [macresearch@macquarie.com](mailto:macresearch@macquarie.com) for access requests.

## Email addresses

[FirstName.Surname@macquarie.com](mailto:FirstName.Surname@macquarie.com)

## Asia Sales

## Regional Heads of Sales

Christina Lee (Head of Asian Sales)	(852) 3922 5854
Alan Chen (HK/China)	(852) 3922 2019
Amelia Mehta (Singapore)	(65) 6601 0211
Paul Colaco (US)	(1 415) 762 5003
Mothlib Miah (UK/Europe)	(44 20) 3037 4893
Anjali Sinha (India)	(9122) 6653 3229
Janeman Latul (Indonesia)	(6221) 2598 8303
Thomas Renz (Geneva)	(41 22) 818 7712
Leslie Hoy (Japan)	(813) 3512 7919

## Regional Heads of Sales cont'd

Tomohiro Takahashi (Japan)	(813) 3512 7823
DJ Kwak (Korea)	(822) 3705 8608
Nik Hadi (Malaysia)	(603) 2059 8888
Gino C Rojas (Philippines)	(632) 857 0861
Richard Liu (Taiwan)	(8862) 2734 7590
Angus Kent (Thailand)	(662) 694 7601

## Sales Trading

Mark Weekes (Asia)	(852) 3922 2084
Sacha Beharie (HK/China)	(852) 3922 2111
Susan Lin (Taiwan)	(8862) 2734 7583
Edward Jones (Japan)	(813) 3512 7822
Douglas Ahn (Korea)	(822) 3705 9990
Stanley Dunda (Indonesia)	(6221) 515 1555
Suhaida Samsudin (Malaysia)	(603) 2059 8888
Michael Santos (Philippines)	(632) 857 0813
Justin Morrison (Singapore)	(65) 6601 0288
Brendan Rake (Thailand)	(662) 694 7707
Alex Johnson (India)	(9122) 6720 4022
Mike Gray (New York)	(1 212) 231 2555
Mike Keen (UK/Europe)	(44 20) 3037 4905